Skip to content
Study details
Enrolling now

Sildenafil for Microvasculopathy in Chronic TBI

University of Pennsylvania
NCT IDNCT05782244ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

160

Study length

about 3.5 years

Ages

18–70

Locations

1 site in PA

About this study

Researchers are testing different doses of sildenafil to see if it can improve blood flow in the brain after a traumatic brain injury. The trial will also look at whether sildenafil improves symptoms and outcomes related to chronic TBI.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Placebo
  • 2.Take Sildenafil Citrate low dose
  • 3.Take Sildenafil high dose
  • +1 more
PhasePhase 2
DrugSildenafil Citrate low dose
Routeoral

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low14%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

Cardiovascular Agent [TC] (Phosphodiesterase 5 Inhibitors), GENITO URINARY SYSTEM AND SEX HORMONES

Drug routes

oral (Oral Suspension), oral (Oral Tablet)

Endpoints

Secondary: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0